Acadia Pharma (ACAD) Misses Q1 EPS by 7c, Revs Beat
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $16.74 -1.47%
Revenue Growth %: +76.2%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
SFST, VLTO, CLIR, More
Revenue Growth %: +76.2%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.59), $0.07 worse than the analyst estimate of ($0.52). Revenue for the quarter came in at $62.96 million versus the consensus estimate of $60.69 million.
GUIDANCE:
Acadia Pharma sees FY2019 revenue of $280-300 million, versus the consensus of $291.2 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Visa (V) earnings and revenue exceed estimates in Q2, shares rise
- Costar Group (CSGP) Tops Q1 EPS by 3c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
